1005194-68-2

Upstream product

• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 41979-39-9 4-piperidone hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 183321-64-4 N-(3-ethynylphenyl)-6-nitroquinazolin-4-amine 
• 193085-24-4 4-carboxymethylenepiperidine-1-carboxylic acid tert-butyl ester 
• 183319-38-2 N⁴-(3-ethynylphenyl)quinazoline-4,6-diamine 

Downstream Products

• 1005194-69-3 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide 
• 1005194-71-7 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide 

Relevant academic research and scientific papers

INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF

The compounds which could inhibit protein tyrosine kinases activity or the pharmaceutical acceptable salts or hydrates thereof. The uses of the compounds in treating or preventing physiological abnormal induced by protein tyrosine kinases overexpression in mammal. The preparation methods of the compounds.

QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS

A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).